ID   DYR1A_HUMAN             Reviewed;         525 AA.
AC   Q13627-4;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 2.
DT   12-OCT-2022, entry version 220.
DE   RecName: Full=Isoform 3 of Dual specificity tyrosine-phosphorylation-regulated kinase 1A;
DE            EC=2.7.11.23 {ECO:0000269|PubMed:25620562};
DE            EC=2.7.12.1 {ECO:0000269|PubMed:20981014, ECO:0000269|PubMed:22998443, ECO:0000269|PubMed:23665168, ECO:0000269|PubMed:24239188, ECO:0000269|PubMed:30773093};
DE   AltName: Full=Dual specificity YAK1-related kinase;
DE   AltName: Full=HP86;
DE   AltName: Full=Protein kinase minibrain homolog {ECO:0000303|PubMed:8872470, ECO:0000303|PubMed:8975710};
DE            Short=MNBH;
DE            Short=hMNB;
GN   Name=DYRK1A {ECO:0000303|PubMed:25620562, ECO:0000312|HGNC:HGNC:3091};
GN   Synonyms=DYRK, MNB {ECO:0000303|PubMed:8872470}, MNBH;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), VARIANT PRO-679, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Fetal brain;
RX   PubMed=8975710; DOI=10.1006/geno.1996.0636;
RA   Song W.J., Sternberg L.R., Kasten-Sportes C., van Keuren M.L., Chung S.H.,
RA   Slack A.C., Miller D.E., Glover T.W., Chiang P.W., Lou L., Kurnit D.W.;
RT   "Isolation of human and murine homologues of the Drosophila minibrain gene:
RT   human homologue maps to 21q22.2 in the Down syndrome 'critical region'.";
RL   Genomics 38:331-339(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), TISSUE SPECIFICITY, AND POSSIBLE
RP   INVOLVEMENT IN DOWN SYNDROME.
RX   PubMed=8872470; DOI=10.1093/hmg/5.9.1305;
RA   Guimera J., Casas C., Pucharcos C., Solans A., Domenech A., Planas A.M.,
RA   Ashley J., Lovett M., Estivill X., Pritchard M.A.;
RT   "A human homologue of Drosophila minibrain (MNB) is expressed in the
RT   neuronal regions affected in Down syndrome and maps to the critical
RT   region.";
RL   Hum. Mol. Genet. 5:1305-1310(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY, AND
RP   DEVELOPMENTAL STAGE.
RC   TISSUE=Fetal brain;
RX   PubMed=8769099; DOI=10.1006/bbrc.1996.1135;
RA   Shindoh N., Kudoh J., Maeda H., Yamaki A., Minoshima S., Shimizu Y.,
RA   Shimizu N.;
RT   "Cloning of a human homolog of the Drosophila minibrain/rat Dyrk gene from
RT   'the Down syndrome critical region' of chromosome 21.";
RL   Biochem. Biophys. Res. Commun. 225:92-99(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Promyelocytic leukemia;
RX   PubMed=9037601; DOI=10.1101/gr.7.1.47;
RA   Ohira M., Seki N., Nagase T., Suzuki E., Nomura N., Ohara O., Hattori M.,
RA   Sakaki Y., Eki T., Murakami Y., Saito T., Ichikawa H., Ohki M.;
RT   "Gene identification in 1.6-Mb region of the Down syndrome region on
RT   chromosome 21.";
RL   Genome Res. 7:47-58(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), TISSUE SPECIFICITY, POSSIBLE
RP   INVOLVEMENT IN DOWN SYNDROME, VARIANTS PHE-415 AND HIS-681, AND ALTERNATIVE
RP   SPLICING.
RX   PubMed=10329007; DOI=10.1006/geno.1999.5775;
RA   Guimera J., Casas C., Estivill X., Pritchard M.A.;
RT   "Human minibrain homologue (MNBH/DYRK1): characterization, alternative
RT   splicing, differential tissue expression, and overexpression in Down
RT   syndrome.";
RL   Genomics 57:407-418(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 234-380.
RC   TISSUE=Fetal brain;
RX   PubMed=9503011; DOI=10.1006/geno.1997.5146;
RA   Dahmane N., Ait-Ghezala G., Gosset P., Chamoun Z., Dufresne-Zacharia M.-C.,
RA   Lopes C., Rabatel N., Gassanova-Maugenre S., Chettouh Z., Abramowski V.,
RA   Fayet E., Yaspo M.-L., Korn B., Blouin J.-L., Lehrach H., Poustka A.,
RA   Antonarakis S.E., Sinet P.-M., Creau N., Delabar J.-M.;
RT   "Transcriptional map of the 2.5-Mb CBR-ERG region of chromosome 21 involved
RT   in Down syndrome.";
RL   Genomics 48:12-23(1998).
RN   [7]
RP   INTERACTION WITH RANBP9, FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=14500717; DOI=10.1074/jbc.m307556200;
RA   Zou Y., Lim S., Lee K., Deng X., Friedman E.;
RT   "Serine/threonine kinase Mirk/Dyrk1B is an inhibitor of epithelial cell
RT   migration and is negatively regulated by the Met adaptor Ran-binding
RT   protein M.";
RL   J. Biol. Chem. 278:49573-49581(2003).
RN   [8]
RP   INTERACTION WITH WDR68.
RX   PubMed=14593110; DOI=10.1074/jbc.m301769200;
RA   Skurat A.V., Dietrich A.D.;
RT   "Phosphorylation of Ser640 in muscle glycogen synthase by DYRK family
RT   protein kinases.";
RL   J. Biol. Chem. 279:2490-2498(2004).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-748 AND SER-758, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [11]
RP   POLY-HISTIDINE REPEATS.
RX   PubMed=19266028; DOI=10.1371/journal.pgen.1000397;
RA   Salichs E., Ledda A., Mularoni L., Alba M.M., de la Luna S.;
RT   "Genome-wide analysis of histidine repeats reveals their role in the
RT   localization of human proteins to the nuclear speckles compartment.";
RL   PLoS Genet. 5:E1000397-E1000397(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-145, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   SUBCELLULAR LOCATION.
RX   PubMed=20167603; DOI=10.1074/jbc.m110.102574;
RA   Guo X., Williams J.G., Schug T.T., Li X.;
RT   "DYRK1A and DYRK3 promote cell survival through phosphorylation and
RT   activation of SIRT1.";
RL   J. Biol. Chem. 285:13223-13232(2010).
RN   [14]
RP   INVOLVEMENT IN MRD7.
RX   PubMed=21294719; DOI=10.1111/j.1399-0004.2010.01544.x;
RA   van Bon B.W., Hoischen A., Hehir-Kwa J., de Brouwer A.P., Ruivenkamp C.,
RA   Gijsbers A.C., Marcelis C.L., de Leeuw N., Veltman J.A., Brunner H.G.,
RA   de Vries B.B.;
RT   "Intragenic deletion in DYRK1A leads to mental retardation and primary
RT   microcephaly.";
RL   Clin. Genet. 79:296-299(2011).
RN   [15]
RP   FUNCTION, AND SUBSTRATE SPECIFICITY.
RX   PubMed=21127067; DOI=10.1074/jbc.m110.157909;
RA   Papadopoulos C., Arato K., Lilienthal E., Zerweck J., Schutkowski M.,
RA   Chatain N., Muller-Newen G., Becker W., de la Luna S.;
RT   "Splice variants of the dual specificity tyrosine phosphorylation-regulated
RT   kinase 4 (DYRK4) differ in their subcellular localization and catalytic
RT   activity.";
RL   J. Biol. Chem. 286:5494-5505(2011).
RN   [16]
RP   INVOLVEMENT IN MRD7.
RX   PubMed=23160955; DOI=10.1126/science.1227764;
RA   O'Roak B.J., Vives L., Fu W., Egertson J.D., Stanaway I.B., Phelps I.G.,
RA   Carvill G., Kumar A., Lee C., Ankenman K., Munson J., Hiatt J.B.,
RA   Turner E.H., Levy R., O'Day D.R., Krumm N., Coe B.P., Martin B.K.,
RA   Borenstein E., Nickerson D.A., Mefford H.C., Doherty D., Akey J.M.,
RA   Bernier R., Eichler E.E., Shendure J.;
RT   "Multiplex targeted sequencing identifies recurrently mutated genes in
RT   autism spectrum disorders.";
RL   Science 338:1619-1622(2012).
RN   [17]
RP   SUBCELLULAR LOCATION.
RX   PubMed=23415227; DOI=10.1016/j.cell.2013.01.033;
RA   Wippich F., Bodenmiller B., Trajkovska M.G., Wanka S., Aebersold R.,
RA   Pelkmans L.;
RT   "Dual specificity kinase DYRK3 couples stress granule
RT   condensation/dissolution to mTORC1 signaling.";
RL   Cell 152:791-805(2013).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14 AND TYR-145, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [19]
RP   INTERACTION WITH HADV5 E1A (MICROBIAL INFECTION).
RX   PubMed=23864635; DOI=10.1128/jvi.00786-13;
RA   Cohen M.J., Yousef A.F., Massimi P., Fonseca G.J., Todorovic B., Pelka P.,
RA   Turnell A.S., Banks L., Mymryk J.S.;
RT   "Dissection of the C-terminal region of E1A redefines the roles of CtBP and
RT   other cellular targets in oncogenic transformation.";
RL   J. Virol. 87:10348-10355(2013).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-529, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [21]
RP   FUNCTION.
RX   PubMed=31024071; DOI=10.1038/s41598-019-42990-5;
RA   Guard S.E., Poss Z.C., Ebmeier C.C., Pagratis M., Simpson H., Taatjes D.J.,
RA   Old W.M.;
RT   "The nuclear interactome of DYRK1A reveals a functional role in DNA damage
RT   repair.";
RL   Sci. Rep. 9:6539-6539(2019).
RN   [22]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=30773093; DOI=10.1080/15384101.2019.1577525;
RA   Menon V.R., Ananthapadmanabhan V., Swanson S., Saini S., Sesay F.,
RA   Yakovlev V., Florens L., DeCaprio J.A., Washburn M.P., Dozmorov M.,
RA   Litovchick L.;
RT   "DYRK1A regulates the recruitment of 53BP1 to the sites of DNA damage in
RT   part through interaction with RNF169.";
RL   Cell Cycle 18:531-551(2019).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 126-490 IN COMPLEXES WITH THE
RP   SYNTHETIC INHIBITORS HARMINE AND INDY, CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=20981014; DOI=10.1038/ncomms1090;
RA   Ogawa Y., Nonaka Y., Goto T., Ohnishi E., Hiramatsu T., Kii I., Yoshida M.,
RA   Ikura T., Onogi H., Shibuya H., Hosoya T., Ito N., Hagiwara M.;
RT   "Development of a novel selective inhibitor of the Down syndrome-related
RT   kinase Dyrk1A.";
RL   Nat. Commun. 1:86-86(2010).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (3.15 ANGSTROMS) OF 128-485, CATALYTIC ACTIVITY, AND
RP   ACTIVITY REGULATION.
RX   PubMed=22998443; DOI=10.1021/jm301034u;
RA   Tahtouh T., Elkins J.M., Filippakopoulos P., Soundararajan M., Burgy G.,
RA   Durieu E., Cochet C., Schmid R.S., Lo D.C., Delhommel F., Oberholzer A.E.,
RA   Pearl L.H., Carreaux F., Bazureau J.P., Knapp S., Meijer L.;
RT   "Selectivity, cocrystal structures, and neuroprotective properties of
RT   leucettines, a family of protein kinase inhibitors derived from the marine
RT   sponge alkaloid leucettamine B.";
RL   J. Med. Chem. 55:9312-9330(2012).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 127-485 IN COMPLEX WITH SYNTHETIC
RP   INHIBITOR, AND CATALYTIC ACTIVITY.
RX   PubMed=24239188; DOI=10.1016/j.bmcl.2013.10.055;
RA   Anderson K., Chen Y., Chen Z., Dominique R., Glenn K., He Y., Janson C.,
RA   Luk K.C., Lukacs C., Polonskaia A., Qiao Q., Railkar A., Rossman P.,
RA   Sun H., Xiang Q., Vilenchik M., Wovkulich P., Zhang X.;
RT   "Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series
RT   of DYRK1B and DYRK1A inhibitors.";
RL   Bioorg. Med. Chem. Lett. 23:6610-6615(2013).
RN   [26]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   LYS-188.
RX   PubMed=25620562; DOI=10.1016/j.molcel.2014.12.026;
RA   Di Vona C., Bezdan D., Islam A.B., Salichs E., Lopez-Bigas N., Ossowski S.,
RA   de la Luna S.;
RT   "Chromatin-wide profiling of DYRK1A reveals a role as a gene-specific RNA
RT   polymerase II CTD kinase.";
RL   Mol. Cell 57:506-520(2015).
RN   [27]
RP   FUNCTION, AND DOMAIN.
RX   PubMed=29849146; DOI=10.1038/s41586-018-0174-3;
RA   Lu H., Yu D., Hansen A.S., Ganguly S., Liu R., Heckert A., Darzacq X.,
RA   Zhou Q.;
RT   "Phase-separation mechanism for C-terminal hyperphosphorylation of RNA
RT   polymerase II.";
RL   Nature 558:318-323(2018).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 127-485 IN COMPLEXES WITH PEPTIDE
RP   SUBSTRATE AND INHIBITOR DJM2005, CATALYTIC ACTIVITY, FUNCTION,
RP   AUTOPHOSPHORYLATION, MUTAGENESIS OF LYS-188 AND TYR-321, PHOSPHORYLATION AT
RP   TYR-111; TYR-140; TYR-159; TYR-177; SER-310; TYR-319; TYR-321; THR-402 AND
RP   TYR-449, ACTIVE SITE, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=23665168; DOI=10.1016/j.str.2013.03.012;
RA   Soundararajan M., Roos A.K., Savitsky P., Filippakopoulos P.,
RA   Kettenbach A.N., Olsen J.V., Gerber S.A., Eswaran J., Knapp S.,
RA   Elkins J.M.;
RT   "Structures of Down syndrome kinases, DYRKs, reveal mechanisms of kinase
RT   activation and substrate recognition.";
RL   Structure 21:986-996(2013).
RN   [29]
RP   VARIANT [LARGE SCALE ANALYSIS] PRO-679.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=Long;
CC         IsoId=Q13627-1; Sequence=Displayed;
CC       Name=1;
CC         IsoId=Q13627-2; Sequence=VSP_004917;
CC       Name=2;
CC         IsoId=Q13627-3; Sequence=VSP_004918, VSP_004919;
CC       Name=3;
CC         IsoId=Q13627-4; Sequence=VSP_004920, VSP_004921;
CC       Name=4;
CC         IsoId=Q13627-5; Sequence=VSP_004922, VSP_004923;
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   ProteomicsDB; 59622; -.
DR   Ensembl; ENST00000645424.1; ENSP00000494897.1; ENSG00000157540.22.
DR   Proteomes; UP000005640; Chromosome 21.
PE   1: Evidence at protein level;
SQ   SEQUENCE   525 AA;  59802 MW;  331976E38527AA3F CRC64;
     MHTGGETSAC KPSSVRLAPS FSFHAAGLQM AGQMPHSHQY SDRRQPNISD QQVSALSYSD
     QIQQPLTNQV MPDIVMLQRR MPQTFRDPAT APLRKLSVDL IKTYKHINEV YYAKKKRRHQ
     QGQGDDSSHK KERKVYNDGY DDDNYDYIVK NGEKWMDRYE IDSLIGKGSF GQVVKAYDRV
     EQEWVAIKII KNKKAFLNQA QIEVRLLELM NKHDTEMKYY IVHLKRHFMF RNHLCLVFEM
     LSYNLYDLLR NTNFRGVSLN LTRKFAQQMC TALLFLATPE LSIIHCDLKP ENILLCNPKR
     SAIKIVDFGS SCQLGQRIYQ YIQSRFYRSP EVLLGMPYDL AIDMWSLGCI LVEMHTGEPL
     FSGANEVDQM NKIVEVLGIP PAHILDQAPK ARKFFEKLPD GTWNLKKTKD GKREYKPPGT
     RKLHNILGVE TGGPGGRRAG ESGHTVADYL KFKDLILRML DYDPKTRIQP YYALQHSFFK
     KTADEGTNTS NSVSTSPAME QSQSSGTTSS TSSSSGGAAL DARCL
//
